4.6 Article

The economic burden of visual impairment and blindness: a systematic review

Journal

BMJ OPEN
Volume 3, Issue 11, Pages -

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/bmjopen-2013-003471

Keywords

Visual Impairment; Blindness; Cost of Illness; Health Economics

Funding

  1. German Research Council [DFG FI 1540/5-5]
  2. Novartis Pharma Germany
  3. Australian National Health and Medical Research Council Centre for Clinical Research Excellence [529923]

Ask authors/readers for more resources

Objectives Visual impairment and blindness (VI&B) cause a considerable and increasing economic burden in all high-income countries due to population ageing. Thus, we conducted a review of the literature to better understand all relevant costs associated with VI&B and to develop a multiperspective overview. Design Systematic review: Two independent reviewers searched the relevant literature and assessed the studies for inclusion and exclusion criteria as well as quality. Eligibility criteria for included studies Interventional, non-interventional and cost of illness studies, conducted prior to May 2012, investigating direct and indirect costs as well as intangible effects related to visual impairment and blindness were included. Methods We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement approach to identify the relevant studies. A meta-analysis was not performed due to the variability of the reported cost categories and varying definition of visual impairment. Results A total of 22 studies were included. Hospitalisation and use of medical services around diagnosis and treatment at the onset of VI&B were the largest contributor to direct medical costs. The mean annual expenses per patient were found to be US$ purchasing power parities (PPP) 12175-14029 for moderate visual impairment, US$ PPP 13154-16321 for severe visual impairment and US$ PPP 14882-24180 for blindness, almost twofold the costs for non-blind patients. Informal care was the major contributor to other direct costs, with the time spent by caregivers increasing from 5.8h/week (or US$ PPP 263) for persons with vision >20/32 up to 94.1h/week (or US$ PPP 55062) for persons with vision 20/250. VI&B caused considerable indirect costs due to productivity losses, premature mortality and dead-weight losses. Conclusions VI&B cause a considerable economic burden for affected persons, their caregivers and society at large, which increases with the degree of visual impairment. This review provides insight into the distribution of costs and the economic impact of VI&B.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available